Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 14/20 | 0.97 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753457 | 0.98 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7440101 | 0.98 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL2752706 | 0.98 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL3817173 | 0.98 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196092 | 0.97 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL7561514 | 0.97 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL652844 | 0.97 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196095 | 0.97 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL12196099 | 0.97 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL1059134 | 0.97 | EPHX1 (1.00) | EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8178570-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060293342-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | EPHX1 1109/4885EPHX2 558/4885KDM4E 2956/4885 |
| US-20060293342-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | EPHX1 1178/4885EPHX2 872/4885KDM4E 486/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | EPHX1 569/4885EPHX2 864/4885KDM4E 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.